MyoKardia nets $116.8mm via FOPO

15:40 EDT 11 Aug 2017 | Elsevier Business Intelligence

Cardiovascular therapeutics developer MyoKardia Inc. netted $116.8mm through the follow-on sale of 3.5mm common shares at $35...

Original Article: MyoKardia nets $116.8mm via FOPO


More From BioPortfolio on "MyoKardia nets $116.8mm via FOPO"

Quick Search

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...